global glp-1 obesity drug market size forecast 2030 Agonists Report 2025-2033, By Product, Molecule, and Geo GLP-1 Obesity Home Delivery Injectables
Description
doi: 10.2337/db12-0797 67 CeglaJTrokeRCJonesBTharakanGKenkreJMcCulloughKAet al
doi:10.3390/jcm12185921
[DOI] [PubMed] [Google Scholar] 9.Vilsbll T, Agers H, Krarup T, et al
In fact, mice with hepatocyte-specific DPP-4 knockdown have a significant reduction in serum DPP-4 activity and reduced adipose tissue inflammation, insulin resistance, and glucose intolerance [20]
Small studies have suggested a parallel reduction in intrapancreatic fat content following initiation of GLP-1RA 52
Pharmacology and Therapeutics
